Search

Displaying results 2001 - 2010 of 10000 in total
  1. Drug

    Golodirsen

    go.drugbank.com/drugs/DB15593
    ApprovedInvestigational

    Often, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications. … [L10755,L10758] Golodirsen was initially rejected for FDA approval over concerns about its potential renal toxicity, however, clinical trials did not show significant toxicity.[L10755]

    International brands: Vyondys 53Products: Vyondys 53
  2. Drug

    Coagulation factor X human

    go.drugbank.com/drugs/DB13148
    ApprovedInvestigational

    Coagulation Factor X (Human) solution is approved by the FDA for intravenous injection under the market name Coagadex which contains normally 100 IU/mL of coagulation Factor X derived from healthy donors … Inherited factor X deficiency is a rare autosomal recessive bleeding disorder that is estimated to occur in 1:1 000 000 individuals up to 1:500 carriers [A31471].

    Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET
  3. Drug

    Phosphoric acid

    go.drugbank.com/drugs/DB09394
    ApprovedInvestigational

    Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and Mg++.

    Mixtures: HEPATAMINE %8 500 ML(SETLI), HEPATAMINE %8 500 ML(SETSIZ)
  4. Drug

    JZP-386 free base

    go.drugbank.com/drugs/DB17068
    Experimental

    JZP-386 is a deuterium-containing analog of sodium oxybate. Its safety, pharmacokinetics and pharmacodynamics were evaluated in clinical trial NCT02215499.

    Synonyms: JZP-386 free base
  5. Drug

    Bretylium

    go.drugbank.com/drugs/DB01158
    Approved

    Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.

    Mixtures: Bretylium Tosylate 0.4% and Dextrose 5% Inj, Bretylium Tosylate 0.2% and Dextrose 5% InjProducts: Bretylate Inj 50mg/ml, Bretylium Tosylate Inj 50mg/ml
  6. Drug

    Siponimod

    go.drugbank.com/drugs/DB12371
    ApprovedInvestigational

    Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). … It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesProducts: MAYZENT FILM-COATED TABLET 2MG
  7. Drug

    Tozinameran

    go.drugbank.com/drugs/DB15696
    ApprovedInvestigational

    Comirnaty is also approved for use as a fourth booster shot in adults 50 years of age and older.[L41350] … [L26996] Full FDA approval was granted on August 23, 2021.

    Mixtures: Comirnaty Original & Omicron Ba.4/ba.5, Comirnaty Original & Omicron Ba.4/ba.5Products: Comirnaty Omicron XBB.1.5 10 micrograms/dose Dispersion for Injection, Comirnaty Omicron XBB.1.5 30 micrograms/dose Dispersion for Injection
  8. Drug

    Opiranserin

    go.drugbank.com/drugs/DB16271
    Investigational

    Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty).

    Synonyms: Vvz-149 free baseCategories: Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists
  9. Drug

    Revaprazan

    go.drugbank.com/drugs/DB16308
    Investigational

    Revaprazan is under investigation in clinical trial NCT01750437 (Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(nerd)).

    Synonyms: Yh-1885 free base
  10. Drug

    BMS-833923

    go.drugbank.com/drugs/DB16844
    Investigational

    Synonyms: BMS-833923 free base anhydrous